Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.

Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.

[1]  H. Masuya,et al.  Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Iwama,et al.  p300 gene alterations in colorectal and gastric carcinomas. , 1996, Oncogene.

[3]  S. Lazo-Kallanian,et al.  Essential Role for the P55 Tumor Necrosis Factor Receptor in Regulating Hematopoiesis at a Stem Cell Level , 1999, The Journal of experimental medicine.

[4]  R. W. Miller,et al.  Tumors in Rubinstein-Taybi syndrome. , 1995, American journal of medical genetics.

[5]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[6]  L. M. Facchini,et al.  The molecular role of Myc in growth and transformation: recent discoveries lead to new insights , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[8]  T. Nabeshima,et al.  Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. , 1999, Human molecular genetics.

[9]  R. Eckner.  p300 and CBP as transcriptional regulators and targets of oncogenic events. , 1996, Biological chemistry.

[10]  M. Breuning,et al.  Conjunction dysfunction: CBP/p300 in human disease. , 1998, Trends in genetics : TIG.

[11]  D. Housman,et al.  MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Jeffrey D. Parvin,et al.  RNA Helicase A Mediates Association of CBP with RNA Polymerase II , 1997, Cell.

[13]  Eric Nyberg,et al.  Independent transformation activity by adenovirus-5 E1A-conserved regions 1 or 2 mutants. , 1991, Virology.

[14]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Potter.  Experimental plasmacytomagenesis in mice. , 1997, Hematology/oncology clinics of North America.

[16]  S. Bacchetti,et al.  Definition of adenovirus type 5 functions involved in the induction of chromosomal aberrations in human cells. , 1990, The Journal of general virology.

[17]  Johnson M Liu,et al.  Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.

[18]  J. Ward,et al.  The Morphology, Immunohistochemistry, and Incidence of Hematopoietic Neoplasms in Mice and Rats , 1993, Toxicologic pathology.

[19]  S. Orkin,et al.  CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Ewen,et al.  The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. , 1994, Cold Spring Harbor symposia on quantitative biology.

[21]  B. Howard,et al.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.

[22]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[23]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[24]  Mariann Bienz,et al.  Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling , 1998, Nature.

[25]  L. Schnipper,et al.  Genetic analysis of adenovirus E1A: induction of genetic instability and altered cell morphologic and growth characteristics are segregatable functions. , 1998, Mutation research.

[26]  T. Suda,et al.  Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. , 1999, Blood.

[27]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[28]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[29]  N. Shiama.  The p300/CBP family: integrating signals with transcription factors and chromatin. , 1997, Trends in cell biology.

[30]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[31]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[32]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[33]  E. Harlow,et al.  Cellular targets for transformation by the adenovirus E1A proteins , 1989, Cell.